Garlic has been used for decades as an important food and additionally for its beneficial properties in terms of nutrition and ancestral therapeutics. In this work, we compare the properties of fresh (WG) and aged (BG) extract obtained from elephant garlic, harvested on Chiloe Island, Chile. BG was prepared from WG with a 20-day aging process under controlled temperature and humidity conditions. We observed that in BG, compounds such as diallyl disulfide decrease, and compounds of interest such as 5-hydroxymethylfurfural (69%), diallyl sulfide (17%), 3H-1,2-Dithiole (22%) and 4-Methyl-1,2,3-trithiolane (16%) were shown to be increased. Using 2,2-diphenyl-1-picrylhydrazyl (DPPH, BG: 51 ± 5.7%, WG: 12 ± 2.6%) and 2,20-azino-bis-(3-ethylbenzothiazoline-6 sulfonate) diammonium salt (ABTS, BG: 69.4 ± 2.3%, WG: 21 ± 3.9%) assays, we observed that BG possesses significantly higher antioxidant activity than WG and increased cell viability in hippocampal slices (41 ± 9%). The effects of WG and BG were shown to improve the neuronal function through an increased in intracellular calcium transients (189 ± 4%). In parallel, BG induced an increase in synaptic vesicle protein 2 (SV-2; 75 ± 12%) and brain-derived neurotrophic factor (BDNF; 32 ± 12%) levels. Thus, our study provides the initial scientific bases to foster the use of BG from Chiloe Island as a functional food containing a mixture of bioactive compounds that may contribute to brain health and well-being.
Alzheimer’s disease (AD) is a significant global health challenge, further exacerbated by the anticipated increase in prevalence in the coming years. The accumulation of β-amyloid peptide plays a critical role in the onset of AD; however, emerging evidence suggests that soluble oligomers of β-amyloid may primarily drive the neuronal impairments associated with this condition. Additionally, neurodegenerative diseases like AD are linked to oxidative stress and reduced antioxidant capacity in the brain. Natural products, particularly polysaccharides extracted from mushrooms, have garnered interest due to their neuroprotective properties and the potential to enhance the value of natural sources in addressing human diseases. This study examines the antioxidant and neuroprotective properties of polysaccharides derived from Cyttaria espinosae Lloyd (CePs), a relatively underexplored fungus native to Chile. Using Fourier Transform Infrared Spectroscopy (FT-IR) and Gas Chromatography-Mass Spectrometry (GC-MS), we characterized CePs. We assessed their antioxidant capacity using DPPH and ABTS assays, yielding maximum inhibition rates of 32.14% and 19.10%, respectively, at a concentration of 10 mg mL−1. CePs showed no toxicity in zebrafish embryos and maintained high cell viability in PC-12 cells exposed to amyloid β peptide (Aβ). Our findings suggest that CePs exhibit significant antioxidant and neuroprotective properties against Aβ peptide toxicity while remaining non-toxic to zebrafish embryos. This underscores the potential of the polysaccharides from this mushroom to serve as functional foods that mitigate oxidative stress and warrant further investigation into their mechanisms in the context of the physiopathology of Alzheimer’s disease.
The accumulation of beta-amyloid (Aβ) oligomers is a critical hallmark for different neurodegenerative conditions, including Alzheimer's disease. The short peptide KLVFF, derived from the central hydrophobic domain of Aβ, binds to Aβ oligomers and interferes with Aβ aggregation. However, the underlying molecular mechanism of action of this peptide remains to be elucidated. This work addresses this question by studying the interaction between Aβ11-42 (Aβ peptide with 32 amino acids length, from residue 11 to 42) hexamer models and an increasing number (n =1, 3, 6) of randomly positioned KLVFF peptides using triplicate microsecond-scale molecular dynamics (MD) simulations. Our findings revealed that KLVFF interacts non-specifically with the fibril model, maintaining a disordered secondary structure. This interaction induces conformational changes at the ends of the hexamer, leading to the gradual detachment of terminal monomers from the fibril. Structural and energetic data suggest an inhibitory mechanism based on the loss of structural integrity and the prevention of ordered Aβ addition at the fibril ends. This proposal differs from the mechanism previously postulated in the literature, according to which KLVFF would disrupt Aβ aggregation by binding to the central hydrophobic domain at an Aβ region that matches the peptide sequence in an amyloid-like secondary conformation. The validity of our computational findings was corroborated by circular dichroism experiments, which confirmed the ability of the KLVFF peptide to reduce the formation of β-sheet secondary structures in Aβ solutions, with a concentration- and incubation time-dependent effect. Additionally, thioflavin T aggregation assays supported the role of KLVFF in reducing the Aβ aggregation propensity with no evidence of KLVFF self-aggregation. These results provide key insights for the rational design of novel Aβ aggregation inhibitors mimicking KLVFF as fibril end destabilizers and hinders of oligomer elongation